Aripiprazole lauroxil regulatory update

Alkermes said FDA accepted for review an NDA for aripiprazole lauroxil to treat schizophrenia. The PDUFA date is Aug. 22, 2015. The product is an extended-release, once-monthly, injectable formulation of aripiprazole using the company's LinkeRx technology. ...